Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

This randomized, double-blind, phase 3 study (56-week treatment; 24-week follow-up) assessed tanezumab in patients with chronic low back pain and history of inadequate response to standard-of-care analgesics (NCT02528253). Patients received placebo, subcutaneous tanezumab (5 or 10 mg every 8 weeks),...

Descripción completa

Detalles Bibliográficos
Autores principales: Markman, John D., Bolash, Robert B., McAlindon, Timothy E., Kivitz, Alan J., Pombo-Suarez, Manuel, Ohtori, Seiji, Roemer, Frank W., Li, David J., Viktrup, Lars, Bramson, Candace, West, Christine R., Verburg, Kenneth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431140/
https://www.ncbi.nlm.nih.gov/pubmed/32453139
http://dx.doi.org/10.1097/j.pain.0000000000001928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431140/
https://www.ncbi.nlm.nih.gov/pubmed/32453139
http://dx.doi.org/10.1097/j.pain.0000000000001928

Ejemplares similares